Pelechas Eleftherios, Voulgari Paraskevi V, Drosos Alexandros A
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece.
J Clin Med. 2019 Mar 20;8(3):387. doi: 10.3390/jcm8030387.
Since the advent of infliximab for the treatment of rheumatoid arthritis (RA), new genetically-engineered molecules have appeared. This review aims to present the current data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity are all being investigated, not only through phase III trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-MORE, GO-FURTHER, GO-NICE), but also through studies of real-world data. It seems that GLM in the subcutaneous form is an efficacious molecule with a good safety profile at the standard dosage scheme, but a 100 mg subcutaneous dose is associated with a higher risk of opportunistic infections, lymphoma and demyelination. Furthermore, when compared to other tumor necrosis factor-α molecules, it is non-inferior, and, at some points, such as when it comes to immunogenicity and persistence of the drug, it has a better profile. In summary, GLM is an effective, well-tolerated option for the treatment of RA, for both the clinician and patients who are seeking a convenient dosage scheme.
自从英夫利昔单抗用于治疗类风湿关节炎（RA）以来，出现了新的基因工程分子。本综述旨在介绍戈利木单抗（GLM）的当前数据和证据。不仅通过III期试验（GO-BEFORE、GO-FORWARD、GO-AFTER、GO-MORE、GO-FURTHER、GO-NICE），还通过真实世界数据研究，对安全性、有效性、耐受性和免疫原性进行了全面调查。皮下注射剂型的GLM似乎是一种有效的分子，在标准剂量方案下具有良好的安全性，但100mg皮下注射剂量与机会性感染、淋巴瘤和脱髓鞘的较高风险相关。此外，与其他肿瘤坏死因子-α分子相比，它并不逊色，并且在某些方面，如免疫原性和药物持久性方面，表现更佳。总之，对于寻求便捷给药方案的临床医生和患者而言，GLM是治疗RA的一种有效且耐受性良好的选择。
